Moonshot technologies

[XenaLives]

Synthetic Biology SABS: Engineered Immunity

Corporate Profile
SAB Biotherapeutics is a clinical-stage biopharmaceutical company leveraging its novel DiversitAb™ platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors. By harnessing the native human antibody immune response, SAB’s platform enables a scalable and reliable production of these highly-efficacious polyclonal therapies with the potential to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. The Company’s lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH’s ACTIV-2 protocol, and SAB-176, a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate designed to bind to Type A and B viruses. Additional pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction/rejection, and SAB-181 for immune globulin (IgG) mediated diseases.

https://ir.sabbiotherapeutics.com/

[XenaLives]

Immortality: Molecluar biology holds the key and while immortality may not be within reach significant reduction of disease and suffering is. Traditional pharma has too many toxic side effects, suppression of symptoms in order to exploit the customer seems to be the end goal.

I have serious doubts about the mRNA covid vax but mRNA is a way to fight cancer and disease:

https://investorshub.advfn.com/CureVac-BV-CVAC-38286/

[XenaLives]

SPAC info site:

https://spacinsider.com/

[XenaLives]

Synthetic Biology: Four medical SPACs planned:

Palihapitiya has led the charge on SPACs, an investment entity that was rarely used before the COVID-19 pandemic but has exploded in usage since the beginning of 2020. Palihapitiya has been credited with starting the trend, with The New Yorker recently proclaiming the former venture-capital investor and early Facebook Inc. FB, +0.80% employee “The Pied Piper of SPACs.” While SPAC filings arrived en masse for almost a year, they have largely paused of late as the SEC casts an eye on their sudden boom as well as their accounting and disclosure practices.

Don’t miss: The SPACsplosion has reached a reckoning

Palihapitiya has led four SPACs, all named Social Capital Hedosophesia Holdings Corp. and differentiated with Roman numerals, through mergers that have led to publicly traded stocks. Space-tourism company Virgin Galactic Holdings Inc . SPCE, +1.25%, health-care software company Clover Health Investments Corp. CLOV, +0.25%, real-estate platform Opendoor Technologies Inc. OPEN, +2.72% and, most recently, financial-technology startup SoFi Technologies Inc. SOFI, +1.78% have gone public through Social Capital SPACs. Two remain: Social Capital Hedosophesia Holdings Corp. IV IPOD, -0.50% and Social Capital Hedosophesia Holdings Corp. VI IPOF, .

With the new batch of SPACs, Palihapitiya is breaking from his previous naming and ticker strategy as he switches his focus to biotech. According to the filings, each of the new SPACs will focus on a different area of biotech: Social Capital Suvretta Holdings Corp. I, with the ticker symbol DNAA, will focus on neurology; Social Capital Suvretta Holdings Corp. II, with the ticker symbol DNAB, will target oncology; Social Capital Suvretta Holdings Corp. III, with the ticker symbol DNAC, will begin with a focus on “the organ space subsector”; and Social Capital Suvretta Holdings Corp. IV, with the ticker symbol DNAD, will look for a merger in the immunology sector.

The “organ space” subsector refers to “intrinsic diseases of the heart, kidney, endocrine system (including diabetes and lipids) and blood compartment (non-oncologic diseases),” the filing explained.

https://www.marketwatch.com/story/chamath-palihapitiya-files-for-four-new-spacs-with-a-new-focus-11622671916

[XenaLives]

Synthetic Biology: “At its core, 'synbio', as the field is commonly referred to, takes advantage of the vast diversity of nature to make biomolecules that traditional chemistry cannot.”

New SPAC came on line this week - still learning about it.

Ginko Bioworks -

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164989324

I expect more companies will be added.

[XenaLives]

RULES FOR THE BOARD -

1) Read the board intro.
2) Preface your post with one of the 14 categories listed.
3) Stay on topic and clearly differentiate between fact and opinion, link to source material when possible.
4) Don't spam the board with tiny details, DD posted here should be key and significant or a summary with links to details that others can follow if interested.